FDA Approves Lynavoy (Linerixibat) for PBC-Related Itching Amid GSK-Alfasigma $690M Deal on March 20, 2026 Alfasigma Approved Cholestatic pruritus Linerixibat Liver diseases Lynavoy Primary Biliary Cholangitis SmithKline Beecham United States Food and Drug Administration +
Alfasigma Licenses GSK's Linerixibat for PBC Itch in Up to $690M Deal on March 11, 2026 Alfasigma Cholestatic pruritus Linerixibat Liver diseases PBC Primary Biliary Cholangitis SmithKline Beecham +
Intercept Withdraws Ocaliva from US Market After FDA Safety Concerns on September 11, 2025 Clinical Trials concerns Drug withdrawal syndrome Injury of liver Intercept Pharmaceuticals Liver diseases Ocaliva Primary Biliary Cholangitis Safety United States Food and Drug Administration +
Gilead's Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment on February 22, 2025 biliary cholangitis Commission Conditional European (ethnic group) Gilead Sciences Primary Biliary Cholangitis Response process seladelpar ursodiol +